Mayo Clinic researchers have found that the urinary incontinence medication oxybutynin (Oxytrol, Ditropan XL) can reduce the severity and frequency of hot flashes in menopausal women who aren’t able to take hormone replacement therapy (HRT), including women who’ve had breast cancer. The researchers presented their findings at the 2018 San Antonio Breast Cancer Symposium.
Hot flashes can have a negative impact on a woman’s quality of life and often are more severe in breast cancer survivors, especially those whose treated with chemotherapy and/or anti-estrogens like tamoxifen or aromatase inhibitors. Oxybutynin is a drug that interferes with neurotransmitters in the brain and nervous system.
The Mayo Clinic study Involved 150 women who had experienced at least 28 hot flashes per week for more than a month. Two groups of women were given different doses of oxybutynin and a third group took a placebo. Women in the first two groups experienced fewer hot flashes and reported better quality of life — that is, hot flashes had less of an impact on their work, social life, leisure activities, and sleep — compared with women in the third group.
Sourced from: Mayo Clinic